Immunome (IMNM) Other Non-Current Liabilities (2020 - 2023)

Immunome's Other Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $1.3 million for Q4 2023.

• Quarterly Other Non-Current Liabilities rose 2061.29% year-over-year to $1.3 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $1.3 million (up 2061.29% YoY) and the FY2023 annual result came in at $1.3 million, up 2061.29% from the prior year.
• Other Non-Current Liabilities was $1.3 million for Q4 2023 at Immunome, up from $122000.0 in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $7.1 million in Q3 2020 and bottomed at $12000.0 in Q4 2021.
• A 4-year average of $1.1 million and a median of $123000.0 in 2022 frame the typical range for Other Non-Current Liabilities.
• Peak annual rise in Other Non-Current Liabilities reached 2061.29% in 2023, while the deepest fall reached 31.18% in 2023.
• Immunome's Other Non-Current Liabilities stood at $7.1 million in 2020, then plunged by 99.83% to $12000.0 in 2021, then jumped by 416.67% to $62000.0 in 2022, then surged by 2061.29% to $1.3 million in 2023.
• Business Quant data shows IMNM's Other Non-Current Liabilities at $1.3 million in Q4 2023, $122000.0 in Q3 2023, and $62000.0 in Q4 2022.